000269681 001__ 269681
000269681 005__ 20240526004109.0
000269681 0247_ $$2doi$$a10.1002/alz.13761
000269681 0247_ $$2pmid$$apmid:38574374
000269681 0247_ $$2pmc$$apmc:PMC11095430
000269681 0247_ $$2ISSN$$a1552-5260
000269681 0247_ $$2ISSN$$a1552-5279
000269681 0247_ $$2altmetric$$aaltmetric:161593455
000269681 037__ $$aDZNE-2024-00595
000269681 041__ $$aEnglish
000269681 082__ $$a610
000269681 1001_ $$00000-0002-9169-7530$$aBollack, Ariane$$b0
000269681 245__ $$aInvestigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.
000269681 260__ $$aHoboken, NJ$$bWiley$$c2024
000269681 3367_ $$2DRIVER$$aarticle
000269681 3367_ $$2DataCite$$aOutput Types/Journal article
000269681 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1716453713_3149
000269681 3367_ $$2BibTeX$$aARTICLE
000269681 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000269681 3367_ $$00$$2EndNote$$aJournal Article
000269681 520__ $$aTo support clinical trial designs focused on early interventions, our study determined reliable early amyloid-β (Aβ) accumulation based on Centiloids (CL) in pre-dementia populations.A total of 1032 participants from the Amyloid Imaging to Prevent Alzheimer's Disease-Prognostic and Natural History Study (AMYPAD-PNHS) and Insight46 who underwent [18F]flutemetamol, [18F]florbetaben or [18F]florbetapir amyloid-PET were included. A normative strategy was used to define reliable accumulation by estimating the 95th percentile of longitudinal measurements in sub-populations (NPNHS = 101/750, NInsight46 = 35/382) expected to remain stable over time. The baseline CL threshold that optimally predicts future accumulation was investigated using precision-recall analyses. Accumulation rates were examined using linear mixed-effect models.Reliable accumulation in the PNHS was estimated to occur at >3.0 CL/year. Baseline CL of 16 [12,19] best predicted future Aβ-accumulators. Rates of amyloid accumulation were tracer-independent, lower for APOE ε4 non-carriers, and for subjects with higher levels of education.Our results support a 12-20 CL window for inclusion into early secondary prevention studies. Reliable accumulation definition warrants further investigations.
000269681 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000269681 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000269681 650_7 $$2Other$$aAlzheimer's
000269681 650_7 $$2Other$$aCentiloid
000269681 650_7 $$2Other$$aamyloid
000269681 650_7 $$2Other$$alongitudinal PET
000269681 650_7 $$2Other$$aquantification
000269681 650_7 $$2Other$$areliable accumulation
000269681 650_2 $$2MeSH$$aHumans
000269681 650_2 $$2MeSH$$aMale
000269681 650_2 $$2MeSH$$aFemale
000269681 650_2 $$2MeSH$$aPositron-Emission Tomography
000269681 650_2 $$2MeSH$$aAged
000269681 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000269681 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000269681 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000269681 650_2 $$2MeSH$$aAniline Compounds
000269681 650_2 $$2MeSH$$aPrognosis
000269681 650_2 $$2MeSH$$aMiddle Aged
000269681 650_2 $$2MeSH$$aLongitudinal Studies
000269681 650_2 $$2MeSH$$aStilbenes
000269681 650_2 $$2MeSH$$aBrain: diagnostic imaging
000269681 650_2 $$2MeSH$$aBrain: metabolism
000269681 650_2 $$2MeSH$$aBenzothiazoles
000269681 7001_ $$00000-0001-6263-1762$$aCollij, Lyduine E$$b1
000269681 7001_ $$00000-0003-3308-3167$$aGarcía, David Vállez$$b2
000269681 7001_ $$00000-0003-1336-6768$$aShekari, Mahnaz$$b3
000269681 7001_ $$00000-0003-1905-8993$$aAltomare, Daniele$$b4
000269681 7001_ $$aPayoux, Pierre$$b5
000269681 7001_ $$aDubois, Bruno$$b6
000269681 7001_ $$aGrau-Rivera, Oriol$$b7
000269681 7001_ $$00000-0003-2617-3009$$aBoada, Mercè$$b8
000269681 7001_ $$00000-0002-0660-0950$$aMarquié, Marta$$b9
000269681 7001_ $$aNordberg, Agneta$$b10
000269681 7001_ $$00000-0001-7346-8200$$aWalker, Zuzana$$b11
000269681 7001_ $$aScheltens, Philip$$b12
000269681 7001_ $$aSchöll, Michael$$b13
000269681 7001_ $$aWolz, Robin$$b14
000269681 7001_ $$aSchott, Jonathan M$$b15
000269681 7001_ $$aGismondi, Rossella$$b16
000269681 7001_ $$00000-0001-5052-6586$$aStephens, Andrew$$b17
000269681 7001_ $$aBuckley, Christopher$$b18
000269681 7001_ $$aFrisoni, Giovanni B$$b19
000269681 7001_ $$00000-0002-3102-6778$$aHanseeuw, Bernard$$b20
000269681 7001_ $$aVisser, Pieter Jelle$$b21
000269681 7001_ $$aVandenberghe, Rik$$b22
000269681 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b23$$udzne
000269681 7001_ $$aYaqub, Maqsood$$b24
000269681 7001_ $$aBoellaard, Ronald$$b25
000269681 7001_ $$00000-0002-6155-0642$$aGispert, Juan Domingo$$b26
000269681 7001_ $$00000-0002-3114-0773$$aMarkiewicz, Pawel$$b27
000269681 7001_ $$00000-0001-7833-616X$$aCash, David M$$b28
000269681 7001_ $$aFarrar, Gill$$b29
000269681 7001_ $$00000-0003-3543-3706$$aBarkhof, Frederik$$b30
000269681 7001_ $$aconsortium, AMYPAD$$b31$$eCollaboration Author
000269681 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.13761$$gVol. 20, no. 5, p. 3429 - 3441$$n5$$p3429 - 3441$$tAlzheimer's and dementia$$v20$$x1552-5260$$y2024
000269681 8564_ $$uhttps://pub.dzne.de/record/269681/files/DZNE-2024-00595%20SUP.pdf
000269681 8564_ $$uhttps://pub.dzne.de/record/269681/files/DZNE-2024-00595.pdf$$yOpenAccess
000269681 8564_ $$uhttps://pub.dzne.de/record/269681/files/DZNE-2024-00595%20SUP.pdf?subformat=pdfa$$xpdfa
000269681 8564_ $$uhttps://pub.dzne.de/record/269681/files/DZNE-2024-00595.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000269681 909CO $$ooai:pub.dzne.de:269681$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000269681 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000269681 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000269681 9141_ $$y2024
000269681 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000269681 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000269681 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-25$$wger
000269681 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000269681 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000269681 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000269681 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000269681 980__ $$ajournal
000269681 980__ $$aVDB
000269681 980__ $$aUNRESTRICTED
000269681 980__ $$aI:(DE-2719)1011202
000269681 9801_ $$aFullTexts